Targeting DGKα improves T cell activation and immune responses in cancer, highlighting potential with checkpoint inhibitors.
The development of selective diacylglycerol kinase alpha (DGKα) inhibitors offers a promising strategy to restore T cell activation and enhance antitumor immunity. Combined with immune checkpoint inhibitors (e.g., PD-1, PD-L1), DGKα inhibitors improve immune response and tumor control, representing a potential breakthrough in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Robert B. Kargbo (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: